The tactics of performing therapeutic trials

Clinical Epidemiology: How to Do Clinical Practice Research: Third Edition

Volumn , Issue , 2012, Pages 66-172

  Sackett, Dave ^a  

^a Kilgore S Trout Research and Education Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84975775460     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (144)

1. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988;296:320-331.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
3. Simon RN. An agenda for Clinical Trials: clinical trials in the genomic era. Clin Trials 2004;1:468-470.
4. Israel E, Chinchilli VM, Ford JG, et al., for the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364:1505-1512.
5. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med. 1979;301:1410-1412.
6. Gent M, Blakely JA, Easton JD, et al. Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220.
7. Hass WK, Easton JD, Adams HP Jr, et al., Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
8. Topol EJ. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905-1914.
9. Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991:404-409.
10. Baigent C. The need for large-scale randomized evidence. Br J Clin Pharmacol 1997; 43:349-353.
11. Horton R. From star signs to trial guidelines. Lancet 2000;355:1033-1034.
12. Meinert CL. Data collection considerations; and data items and forms illustrations. Clinical trials; design, conduct and analysis. Oxford: Oxford University Press, 1986:119-137 and 379-416.
13. Pocock SJ. Forms and data management. Clinical trials; a practical approach. Chichester, UK: John Wiley & Sons, 1983:160-166.
14. Spilker B. Preparing data collection forms. Guide to clinical trials. Philadelphia, PA: J.B. Lippincott, 1991:262-271.
15. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in health care trials (Cochrane Review). The Cochrane Library, (Issue 3). Oxford: Update Software, 2002.
16. Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect.". J Clin Epidemiol 2001;54:217-224.
17. Vist GE, Hagen KB, Devereaux PJ, et al. Outcomes of patients who participate in randomised controlled trials versus those of similar patients who do not participate (Protocol for a Cochrane Review). The Cochrane Library, (Issue 3). Oxford: Update Software, 2002.
18. Ferguson D, Aaron SD, Guyatt G, et al. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002;325:652-654.
19. Moher D, Schulz KF, Altman D, The CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1991.
20. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359:614-618.
21. Hallstrom AP, Paradis NA. Pre-randomization and de-randomization in emergency medical research: new names and rigorous criteria for old methods. Resuscitation Resuscitation. 2005;65:65-69.
22. Schulz KF, Chalmers I, Grimes DA, et al. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994;13:125-128.
23. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II. Mortality results. Diabetes 1970;19:785-830.
24. Seltzer H. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program. Diabetes 1972;21:976-979.
25. Cornfield J, The University Group Diabetes Program. A further statistical analysis of the mortality findings. JAMA. 1971;217:1676-1687.
26. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974;15:443-453.
27. Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976;1:1265-1268.
28. Schulz KF, Grimes DA. Generation of allocation sequences in randomized trials: chance, not choice. Lancet 2002;359:515-519.
29. Treasure T, MacRae KD. Minimization: the platinum standard for trials? BMJ 1998;317: 362-363.
30. Peto R. Clinical trial methodology. Biomedicine Special Issue 1978;28:24-36.
31. Devereaux PJ, Manns BJ, Ghali WA, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001;285:2000-2003.
32. Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002;347:81-88.
33. Horng S, Miller FG. Is placebo surgery unethical? N Engl J Med 2002;347:137-139.
34. Manandhar DS, Orsin D, Shrestha BP et al, MIRA Makwanpur trial team. Effect of a participatory intervention with women's groups on birth outcomes in Nepal: clusterrandomised controlled trial. Lancet 2004;364:970-979.
35. The Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clin Trials 2004;1:91-107.
36. Meinert CL. Sequential versus fixed sample size designs. Clinical trials; design, conduct and analysis. Oxford: Oxford University Press, 1986:72-74.
37. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials, 3rd ed. Berlin: Springer-Verlag, 1998:72-73.
38. Sackett DL. Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinical trialist is ever likely to need (or understand!). CMAJ 2001;165:1226-1237.
39. Kahn KS, Daya S, Colins JA, et al. Empirical evidence of bias in infertility research: overestimation of treatment effect in crossover trials using pregnancy as the outcome measure. Fertil Steril 1996;65:939-945.
40. Pocock SJ. Clinical trials; a practical approach. Chichester, UK: John Wiley & Sons, 1983:110-122.
41. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979;300:1242-1245.
42. Ellenberg SS. Randomization designs in comparative clinical trials. N Engl J Med 1984; 310:1404-1408.
43. The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of a randomized trial. N Engl J Med 1985;313: 1191-1200.
44. Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002;347:81-88.
45. Goldstein AJ, de Beurs E, Chambless DL, et al. EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditions. J Consult Clin Psychol 2000;68:947-956.
46. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-1114.
47. Sackett DL. Turning a blind eye: Why we don't test for blindness at the end of our trials. BMJ 2004;328:1136-113a. May
48. Veterans Administration Cooperative Study Group on Antihypertensive Agents. I. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028-1034.
49. Haynes RB, Taylor DW, Sackett DL, eds. Compliance in health care. Baltimore, MD: The Johns Hopkins University Press, 1979.
50. Haynes RB, McDonald H, Garg AX, et al. Interventions for helping patients to follow prescriptions for medications (Cochrane Review). In: The Cochrane Library, (Issue 3). Oxford: Update Software; 2002.
51. Thomson O'Brien MA, Oxman AD, Davis DA, et al. Audit and feedback versus alternative strategies: effects on professional practice and health care outcomes (Cochrane Review). In: The Cochrane Library, (Issue 3). Oxford: Update Software; 2002.
52. Thomson O'Brien MA, Freemantle N, Oxman AD, et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes (Cochrane Review). In: The Cochrane Library, (Issue 3). Oxford: Update Software; 2002.
53. Thomson O'Brien MA, Oxman AD, Davis DA, et al. Educational outreach visits: effects on professional practice and health care outcomes (Cochrane Review). In: The Cochrane Library, (Issue 3). Oxford: Update Software; 2002.
54. Hayden GF. Alliteration in medicine: a puzzling profusion of p's. BMJ 1999;319:1605-1608.
55. Yusuf S, Sleight P, Pogue J et al., The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
56. Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-2559.
57. Hughes MD, Society for Clinical Trials. Experience with the validation of surrogate endpoints in HIV. New Orleans, LA, May 2004.
58. Currie GP, Lee DK, Haggart K, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003;167:1232-1238
59. Guyatt GH, Cranney A, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin North Am. 2002;31:659-680.
60. D'Agostino RB. Debate: The slippery slope of surrogate outcomes. Curr Control Trials Cardiovasc Med 2000;1:76-78.
61. DeGruttola VG, Clax PC, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 2001;22:485-502.
62. Bucher H, Guyatt G, Cook D, et al. Therapy and applying the results. Surrogate outcomes. In: Guyatt G, Rennie D, eds. Users' guides to the medical literature. Chicago, IL: AMA Press, 2002.
63. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-2220.
64. Sackett DL, Haynes RB, Gent M. Compliance. In: Inman WHW, ed. Monitoring for drug safety, Lancaster, CA: MTP Press, 1980.
65. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-1114.
66. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
67. Myers MG, Cairns JA, Singer J. The consent form as a possible cause of side effects. Clin Pharmacol Ther 1987;42:250-253.
68. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313:1369-1375.
69. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1976;34:585-612, and 1977;35:1-39.
70. Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991:461.
71. Pocock SJ, Assmann SE, Enos LE, et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917-2930.
72. Haynes RB, Taylor DW, Sackett DL, et al. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Prevention of functional impairment by endarterectomy for symptomatic high-grade carotid stenosis. JAMA 1994;271:1256-1259.
73. O'Brien JR, Etherington MD. How much aspirin? Thromb Haemost 1990;64:486.
74. Taylor DW, Barnett HJM, Haynes RB et al, ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet 1999;353:2179-2184.
75. Sackett DL, Haynes RB, Guyatt GH, et al. Clinical epidemiology, 2nd ed. Boston, MA: Little, Brown and Company, 1991:13.
76. Altman DG. Practical statistics for medical research. London: Chapman & Hall, 1991.
77. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-481.
78. Donner A, Klar N. Design and analysis of cluster randomized trials in health research. London: Arnold, 2000.
79. Bailar L. Hormone-replacement therapy and cardiovascular diseases. N Engl J Med 2003;349:521-522.
80. James W. What pragmatism means. Pragmatism: a new name for some old ways of thinking. New York: Longman Green and Company 1907:17-32.
81. Schmid CH, Lau J, McIntosh MW, et al. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med 1998;17:1923-1942.
82. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 2002;31:72-76.
83. McAlister FA, Straus SE, Guyatt GH, et al. Evidence-Based Medicine Working Group. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. JAMA 2000;283:2829-2836.
84. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-454.
85. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793-797.
86. Meinert CL. Clinical trials, design, conduct, and analysis. New York: Oxford University Press, 1986:215-216.
87. Bosch J, Yusuf S, Pogue J, et al. On behalf of the HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002;324:1-5.
88. ... Badrinath, AP Wakeman, JG Wakeman Preventing stroke with ramipril (Letter). BMJ 2002;325:439.
89. Yusuf S, Bosch J, Sleight P. Responding to issues raised (Electronic letter). BMJ 2003;326:52
90. Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ 1994; 309:761-764.
91. Fahey T, Griffiths S, Peters TJ. Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ 1995;311:1056-1059.
92. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med 1987;317:426-432.
93. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
94. Freiman JA, Chalmers TC, Smith H Jr, et al. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med 1978;299:690-694.
95. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA 1994;272:122-124.
96. Detsky AS, Sackett DL. When was a "negative" clinical trial big enough? How many patients you needed depends on what you found. Arch Intern Med 1985;145:709-712.
97. Chalmers I. Proposal to outlaw the term 'negative trial.' BMJ 1985;290:1002.
98. Chan AW, Krleza-Jeric K, Schmid I, et al. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004;171:735-740.
99. Roberts R, Hoey J. An amnesty for unpublished trials. CMAJ 1997;157:1548.
100. Medical Editors Trial Amnesty. Fax: 0171-383-6418. BMJ, BMA House, Tavistock Square, London WC1H 9JR., UK or send by e-mail to: mailto:Meta@ucl.ac.uk
101. Clarke M, Alderson P, Chalmers I. Dis sections in reports of controlled trials published in general medical journals. JAMA 2002;287:2799-2801.
102. McAlister FA, Straus SE, Sackett DL, et al. Analysis and reporting of factorial trials: a systematic review. JAMA 2003;289(19):2545-2553.
103. Guyatt GH, Juniper EF, Walter SD, et al. Interpreting treatment effects in randomised trials. BMJ 1998;316:690-693.
104. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials, 3rd ed. New York: Springer-Verlag, 1998:120 ff.
105. Klar N, Donner A. Current and future challenges in the design and analysis of cluster randomization trials. Stat Med 2001;20:3729-3740.
106. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials, 3rd ed. New York: Springer-Verlag, 1998:112 ff.
107. Ross S, Grant A, Counsell C, et al. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 1999;52:1143-1156.
108. Mapstone J, Elbourne D, Roberts I. Strategies to improve recruitment to research studies (Cochrane Review). In: The Cochrane Library, (Issue 1). Chichester, UK: John Wiley & Sons, 2004.
109. Sackett DL. Why randomized controlled trials fail but needn't: 1. Failure to gain "coalface" commitment and to use the uncertainty principle. CMAJ 2000;162:1311-1314.
110. The EC/IC Bypass Study Group. The international cooperative study of extracranial/intracranial arterial anastomosis (EC/IC Bypass Study): methodology and entry characteristics. Stroke 1985;16:397-406.
111. Wootton R, Bloomer SE, Corbett R, et al. Multicentre randomised control trial comparing real time teledermatology with conventional outpatient dermatological care: societal cost-benefit analysis. BMJ 2000;320:1252-1256.
112. Thomson O'Brien MA, Oxman AD, Haynes RB, et al. Local opinion leaders: effects on professional practice and health care outcomes (Cochrane Review). In: The Cochrane Library, (Issue 1). Oxford: Update Software, 2001.
113. Warlow C. Clinical research under the cosh again. This time it is ethics committees BMJ 2004;329:241-242.
114. Rothman KJ. The continuing unethical use of placebo controls. N Engl J Med 1994; 331:394-398. (plus the subsequent correspondence and rebuttals)
115. Angell M. Investigators' responsibilities for human subjects in developing countries. N Engl J Med 2000;342:967-969. (plus the subsequent correspondence and rebuttals)
116. Lo B, Bayer R, The Ethics Working Group of the HIV Prevention Trials Network. Establishing ethical trials for treatment and prevention of AIDS in developing countries. BMJ 2003;327:337-339.
117. Bhutta Z. Standards of care in research: should reflect local conditions and not the best western standards. BMJ 2004;329:1114-1115.
118. Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect.". J Clin Epid 2001;54:217-224.
119. Vist GE, Hagen KB, Devereaux PJ, et al. Outcomes of patients who participate in randomised controlled trials versus those of similar patients who do not participate (Protocol for a Cochrane Review). In: The Cochrane Library, (Issue 2). Oxford: Update Software, 2003.
120. Di Blasi Z, Kaptchuk TJ, Weinman J, et al. Informing participants of allocation to placebo at trial closure: postal survey. BMJ 2002;325:1329-1331.
121. Marnocha RM. Clinical research: business opportunities for pharmacy-based investigational drug services. Am J Health Syst Pharm 1999;56:249-252.
122. Canadian Medical Association Policy. Physicians and the pharmaceutical industry (Update 2001). CMAJ 2001;164:1339-1341.
123. Bodenheimer T. Uneasy alliance-clinical investigators and the pharmaceutical industry. N Engl J Med 2000;342:1539-1544.
124. Davidoff F, DeAngelis C, Drazen JM, et al. Sponsorship, authorship, and accountability. Lancet 2001;358:854-856.
125. Angelini G, Taylor FC, Reeves BC, et al. Early and midterm outcome after off-pump and on-pump surgery in beating heart against cardioplegic arrest studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials. Lancet 2002;359:1194-1199.
126. Waksman R, Raizner AE, Yeung AC, et al. The INHIBIT investigators. Use of localized intracoronary ß radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 2002;359:551-557.
127. Sackett D, Sackett B. A survey of the credibility of identical trial results when generated by independent investigators or by drug manufacturers. Society for clinical trials annual meeting 2004.
128. Lievre M, Menard J, Brucket E, et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ 2001;322:603-606.
129. Black HR, Elliott WJ, Grandits G et al, The CONVINCE Research Group. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003;289:2073-2082.
130. Psaty BM, Rennie D. Stopping medical research to save money. A broken pact with researchers and patients. JAMA 2003;289:2128-2131.
131. Hopewell S, Clarke M, Stewart L, et al. Time to publication for results of clinical trials (Cochrane Review). In: The Cochrane Library, (Issue 2). Oxford: Update Software, 2003.
132. Scherer RW, Langenberg P. Full publication of results initially presented in abstracts (Cochrane Review). In: The Cochrane Library, (Issue 2). Oxford: Update Software; 2003.
133. Chalmers I. All unbiased comparative studies should be published. BMJ 2002;324:483.
134. Flanigin A, Carey LA, Fontanarosa PB, et al. Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 1998;280:222-224.
135. Arlen H, Mercer J. "Ac-Cent-Tchu-Ate the Positive." Circa 1945. http://www.leoslyrics.com/listlyrics.php?id=8492
136. Larkin M. Whose article is it anyway? Lancet 1999;354:136.
137. Sackett DL, Oxman AD. HARLOT plc: an amalgamation of the world's two oldest professions. BMJ 2003;327:1442-1445.
138. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. BMJ 2002;324:723-729. (The rapid electronic responses make for lively reading!)
139. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-617.
140. Topol EJ, Armstrong P, Van de Werf F et al, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. J Am Coll Cardiol 1992;19:1123-1128.
141. Ellenberg SS. Independent data monitoring committees: rationale, operations and controversies. Stat Med 2001;20:2573-2583.
142. Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: A practical perspective. Chichester, UK: John Wiley & Sons, 2003.
143. Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA; and the DAMOCLES study group. Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005;9:1-238.
144. Meinert CL. Masked monitoring in clinical trials -blind stupidity? N Engl J Med 1998; 338:1381-1382.